CEBPG Exhibits Allele-Specific Expression in Human Bronchial Epithelial Cells

Thomas M. Blomquist¹†, Ronald D. Brown¹†, Erin L. Crawford¹, Ivana de la Serna², Kandace Williams², Youngsook Yoon¹, Dawn-Alita Hernandez¹ and James C. Willey¹

¹Department of Medicine, University of Toledo Medical Center, Toledo, USA. ²Department of Biochemistry, University of Toledo Medical Center, Toledo, USA. †These authors contributed equally to this work.
Corresponding author email: james.willey2@utoledo.edu

Abstract: Inter-individual variation in CCAAT/enhancer binding protein gamma (CEBPG) transcript expression in normal human bronchial epithelial cells (NBEC) is associated with predisposition to lung cancer. We hypothesize that this inter-individual variation is in part explained by cis-acting genetic variation in CEBPG. To test this hypothesis we measured transcript expression derived from each parental copy of CEBPG (ie, allele-specific expression; ASE). There was a significant 2.9-fold higher cell cycle-specific variation in ASE of CEBPG rs2772 A compared to C allele (P = 0.001). In 20% of NBEC samples, CEBPG rs2772 A allele was expressed on average 2.10 fold greater than rs2772 C allele. These data support the hypothesis that genetic variation in linkage disequilibrium with rs2772 influences regulation of CEBPG transcript expression through a trans-effect downstream of RNA polymerase II transcription and confirm that cis-acting genetic variation contributes to inter-individual variation in CEBPG transcript expression in NBEC, which is associated with variation in lung cancer risk.

Keywords: allele-specific expression, CEBPG, normal bronchial epithelial cells, lung cancer, cystic fibrosis, emphysema, cell-cycle, proliferation, airway epithelium
Introduction

The CCAAT/enhancer binding protein (CEBP) family of transcription factors is integral to normal functioning of a wide variety of cellular processes in numerous tissues.\(^1\) Dimerization of CEBP transcription factors is required for recognition and binding of palindromic cytidine-cytidine-adenosine-adenosine-thymidine (CCAAT) box DNA motifs.\(^1,2\) Once dimerized and bound to DNA, CEBP family members regulate transcription of nearby genes through recruitment of co-regulatory and basal transcriptional machinery.\(^1\) Regulation is achieved through a trans-regulatory domain shared by all but one CEBP family member, CCAAT/enhancer binding protein gamma (CEBPG). Because it lacks this trans-domain, under certain conditions CEBPG serves as a regulator and buffering reservoir against the transcriptional activities of the other CEBP family members.\(^1,2\)

Previous studies support the conclusion that CEBPG is the primary transcription factor responsible for regulating key antioxidant and DNA repair transcript levels in normal human bronchial epithelial cells (NBEC).\(^3–5\) and that transcriptional regulation by CEBPG is dysregulated in NBEC of those individuals predisposed to lung cancer.\(^4,5\) In other studies, mice without CEBPG exhibit emphysematous lung histology, abnormally low type II pneumocyte density and early death, which suggests that expression of CEBPG is in part responsible for the promotion of normal airway epithelial cell development and proliferation.\(^6\) Targeted disruption of only one other CEBP family member, CCAAT/enhancer binding protein alpha (CEBPA), results in abnormal lung histology.\(^7,8\) However, in contrast to mice who lack CEBPG, mice without CEBPA display hyperproliferation of type II pneumocytes. These contrasting effects on pneumocyte development and proliferation may be a manifestation of the co-regulatory relationship between CEBPG and CEBPA.\(^2\) It is likely that regulation of CEBPG transcript expression affects airway epithelial proliferative patterns indirectly by modulating CEBPA function and JNK/JunD activity through heterodimerization.\(^9,10\) In turn, this relationship regulates E2F1 transcript levels, and both E2F1 and JNK/JunD activity directly participate in the control of cell proliferation.\(^9,10\) Recently, a haplotype comprising a polymorphic cluster (rs10518275 and rs4805877) in strong linkage disequilibrium with polymorphic site rs2772 in Exon 2 of CEBPG was found to be associated with altered severity of cystic fibrosis lung disease.\(^11\) These findings, in conjunction with previous reports from our lab and others, suggest that cis-acting genetic variation is in part responsible for altered CEBPG transcript expression levels, which in turn may modify severity and risk for a variety of lung pathologies including lung cancer; possibly through dysregulation of airway epithelial cell proliferation and development, as well as antioxidant and DNA repair capacity.\(^3–6\)

In this study, we sought to determine if genetic variation at cis-acting sites contributes to inter-individual variation in CEBPG transcript expression in normal human bronchial epithelial cells (NBEC). The effect of cis-acting genetic variants typically is not observable as variation in total mRNA expression due to often more pronounced trans-effects.\(^12\) Thus, to test this hypothesis we measured allele-specific expression (ASE); that is, the transcript expression derived from each parental copy of CEBPG within individual samples.\(^13\) Because each cis-acting allele within the same cell is subject to exactly the same trans-effect at all times, allele-specific expression differences become more apparent.\(^13,14\)

To better isolate the effect of cis-acting genetic variation on CEBPG expression using ASE we sought to establish an experimental cell-culture system in which substantial variation in trans-factors regulating CEBPG could be induced experimentally. We reasoned that variation in one or more of the trans-factors regulating CEBPG transcript levels would act through cis-regulatory sites and that genetic variation (heterozygosity) at those regulatory sites would result in a different level of transcript produced from each parental chromosome. Using this approach we could narrow down which cis-acting genetic variant(s) influence CEBPG transcript expression, and then derive their general mechanism of action. In previous studies we determined that cell-cycle specific trans-effects regulate CEBPG transcript levels.\(^3,14\) Therefore, for these studies we employed a cycle-synchronized cell line model and, as trans-effects varied during the cell cycle, we measured CEBPG ASE using allele-specific competitive PCR.\(^14\) We also investigated whether observed RNA polymerase II (RNAPII) activity exhibited bias in transcription between the parental copies.\(^15\) This approach was designed to answer whether any ASE resulting from trans-effects on cis-act-
ing genetic variation was due to effects on transcription rate, which would be measurable as RNAPII activity, or effects on a mechanisms downstream of RNAPII activity (ie, post-transcriptional; eg, micro-RNA consensus site modification). We applied this same ASE analysis to NBEC complementary DNA (cDNA) from 15 human subjects to also assess whether cis-acting genetic variation alters transcript expression derived from each parental copy in primary normal human airway epithelium.

**Materials and Methods**

**Design of allele-specific competitive template internal standards**

A competitive template internal standard was prepared for each allele at the rs2772 polymorphic site in Exon 2 of the CEBPG gene according to previously described ASE measurement methods (Fig. 1A and B).\(^1\)\(^4\) Each internal standard was designed to include: (1) a small internal sequence deletion to permit electrophoretic size separation from the co-amplified native template (Fig. 1B) and (2) the same forward and reverse priming sites as the corresponding native template to ensure equivalent amplification upon use of the same primers.\(^1\)\(^6\) The only differences between competitive templates for each allele were: (1) the 3’-terminus sequence of the priming site directly overlying the polymorphic site of interest and (2) a difference in the size of the small internal deletion allowing for electrophoretic size separation between each competitive template (Fig. 1B). Newly synthesized allele-specific internal standards were individually quantified on an Agilent 2100 Bioanalyzer using DNA Chips with DNA 1000 Kit reagents for visualization according to manufacturer’s protocol (Agilent Technologies Deutschland GmbH, ACBD).
Waldbronn, Germany). Quantified internal standards were then combined in a known stochiometric molar ratio (1:1) to create a stock concentrated standardized mixture of internal standards (SMIS). This mixture of allele-specific internal standards was serially diluted to working concentrations,\(^\text{16}\) then used in all subsequent experiments as a reference mixture of standards for quantifying absolute and/or relative allelic levels in native DNA samples. Further details regarding the design and use of allele-specific internal standards in competitive PCR are available as supplementary material online.

### Measurement of allele-specific CEBPG expression

Total RNA was extracted from A549 cell-line and NBEC using TriReagent and reverse transcribed using M-MLV reverse transcriptase and oligo-dT primers as previously described.\(^\text{4}\) Genomic DNA was extracted as previously described. In order to maximize information obtainable from the very small NBEC cDNA samples, the region used for allele-specific measurement of CEBPG Exon 2 was pre-amplified using a non allele-specific primer pair (Supplementary Materials Online). CEBPG transcript abundance in terms of transcript copy number/\(\mu\)L cDNA was determined previously for each of the samples used in this study.\(^\text{4,5}\) Based on these results, it was possible to determine the necessary volume of each cDNA sample to ensure at least 1,000 copies of transcript in each reaction in order to eliminate effect of stochastic sampling variation.\(^\text{17}\)

The presence of genomic material in cDNA before pre-amplification was controlled for by using commercially available reagents for measurement of genomic DNA contamination (Accugenomics, Wilmington, NC). Following pre-amplification, Exon 2 amplicons were quantified by densitometry using an Agilent 2100 Bioanalyzer, and subsequently diluted to \(10^{-13}\) molar concentration. Allele-specific competitive PCR was then performed by combining a 1 \(\mu\)L aliquot of pre-amplified Exon 2 from either cDNA or gDNA with a 1 \(\mu\)L aliquot of \(10^{-13}\) molar standardized mixture of allele-specific internal standards in parallel PCR reactions with a primer set specific to each allele. After allele-specific amplification, products were electrophoretically separated and quantified on an Agilent 2100 Bioanalyzer. Each CEBPG allele was measured in triplicate from a single pre-amplification of each cDNA or gDNA sample. Allele-specific measurement of polymorphic site rs2772 in CEBPG Exon 2 of A549 ChIP DNA was done as described for measurement of allele-specific CEBPG expression in A549 and NBEC cDNA. Sequence information for pre-amplification and allele-specific primers is reported in supplementary materials online.

### Cell-line samples

In order to measure transcript expression from each parental copy of CEBPG in a single sample (also known as allele-specific expression; ASE), a genetic marker informing from which parental copy the transcript was derived must be present. Polymorphic site rs2772 (A and C alleles) was chosen as the transcribed marker for these studies, as it is the only known polymorphic site with a minor allele frequency >10% that is present in CEBPG processed mRNA (Fig. 1A). Based on Hardy-Weinberg Equilibrium assumptions, it was anticipated that ~20%-30% of samples would be heterozygous, and thus usable for measuring transcript expression from each parental copy of CEBPG with ASE measurement approach. 8 human lung carcinoma cell-lines were genotyped using traditional sequencing methods for heterozygosity at polymorphic site rs2772 (University of Iowa DNA Sequencing Facility). Of the 8 cell-lines, only A549 cell-line was heterozygous at rs2772, and hence could be used for these studies.

### A549 cell culture and cell-cycle synchronization model

A549 was cultured using RPMI 1640% + 10% FBS. A double thymidine block (DTB) was used to achieve cell-cycle synchronization in A549 cell-line as previously described.\(^\text{18}\) Cells were seeded into T-75 flasks (no double thymidine block control, 0, 2, 4, 6, 8, 10 and 12 hours post double thymidine block time points) at a predetermined density such that they were 60% confluent at the time of the first thymidine block. Cells were harvested at appropriate time points; no block and 0 hour time points were harvested immediately. For each time point, following cell counting, aliquots were taken for RNA, flow cytometric analysis and Chromatin Immunoprecipitation analysis (ChIP). Total RNA was extracted from 500,000 cells using TriReagent. 1.5 million cells were resuspended and flash frozen in citrate buffer
for flow cytometric analysis, and at least 4 million cells were processed for ChIP. Cell-cycle phase distribution was monitored using propidium iodide for nuclear staining, followed by subsequent detection using a Beckman/Coulter EPICS Elite flow cytometer as previously described. The resulting data were analyzed by Multicycle software (Phoenix Flow Systems) and reported as the percentage of cells in S, G1 or G2/M phase. Complete details regarding chromatin immunoprecipitation (ChIP) methodology using normal rabbit polyclonal IgG sc-2027 control (Santa Cruz Biotechnology, Santa Cruz, CA), or rabbit polyclonal to RNA polymerase II CTD repeat YSPTSPS phospho-S2 (Abcam Inc., Cambridge, MA) antibodies can be found in supplementary materials online. For both E2F1 (cell-cycle biological positive control), ACTB (cDNA loading control) and CEBPG genes, total expression as well as total DNA pull down from ChIP was measured using previously described reagents. E2F1 was chosen as a biological positive control for our cell-cycle experiments as its expression is regulated to some extent at the level of transcription.

Subjects
Normal bronchial epithelial cell (NBEC) samples from forty subjects were included in this study. Subjects were recruited at University of Toledo Medical Center (UTMC) according to a protocol approved by the UTMC institutional review board. Inclusion criteria for the subjects were: willingness and ability to give informed consent, scheduled for diagnostic bronchoscopy, and age between 18 and 90. Exclusion criteria were: HIV, Hepatitis B or C, TB infection, or medical instability. Pregnant women and prisoners were also excluded. For each participating subject, a NBEC sample was obtained by 3–5 cytology brush biopsies of grossly normal bronchial epithelium according to previously described methods. For patients with known lung cancer diagnosis, sampling of NBEC was performed in the lung not involved with cancer. There were no patient adverse events resulting from collecting NBEC. All 40 patient samples were genotyped using traditional sequencing methods for heterozygosity at polymorphic site rs2772 (University of Iowa DNA Sequencing Facility). Of these subjects, 15 were heterozygous at polymorphic site rs2772, and subjected to additional genotyping at polymorphic sites in and around CEBPG representing the most common haplotype pairings representing greater than 95% of individuals: rs736682, rs17530479, rs17530508, rs1469084, rs16968029, rs3745968, and rs36101103. Genotyping data and biographical characteristics of the 15 individuals are presented in Tables 1 and 2.

Table I. Patient sample information.

| Sample ID | Age (years) | Gender | Lung cancer (histology) | Smoking Hx (pack years) | Race |
|-----------|-------------|--------|-------------------------|-------------------------|------|
| 261       | 73          | F      | No                      | 0                       | W    |
| 287       | 65          | F      | Yes (NSCLC)             | 50                      | W    |
| 389       | 55          | M      | No                      | 80                      | W    |
| 521       | 63          | F      | Yes (NSCLC)             | ?                       | ?    |
| 532       | 80          | F      | No                      | 36                      | W    |
| 572       | 74          | M      | Yes (AC)                | 1                       | W    |
| 648       | 80          | F      | No                      | 45                      | W    |
| 247       | 75          | F      | Yes (SQ)                | 50                      | W    |
| 298       | 48          | M      | No                      | 12                      | W    |
| 670       | 66          | M      | Yes (NSCLC)             | 30                      | W    |
| 289       | 68          | F      | Yes (AC)                | ?                       | W    |
| 574       | 63          | M      | Yes (NSCLC)             | 10                      | AA   |
| 262       | 52          | M      | Yes (SQ)                | ?                       | W    |
| 443       | 41          | M      | No                      | 15                      | W    |
| 271       | 58          | M      | Yes (AC)                | 94.5                    | W    |

Note: Demographic patient information for the fifteen individuals heterozygous at CEBPG rs2772.
Abbreviations: NSCLC, Non-Small Cell Lung Cancer; SQ, Squamous Carcinoma; AC, Adenocarcinoma; W, Caucasian; AA, African-American.
Statistical analysis
Bartlett’s test was used to assess homogeneity of variances between log-transformed ASE measurements performed in all gDNA and cDNA. Fisher’s distribution test (F-test) was used to assess intergroup variation in allele-specific CEBPG transcript expression in cDNA samples compared to allele-specific CEBPG products from corresponding gDNA samples. Student’s T-test was performed to assess significance of deviation in central tendency of individual NBEC cDNA total and ASE measurements relative to corresponding gDNA controls, as well as measurements obtained from individual time points in A549 cell-cycle synchronized samples. Bonferroni correction for multiple hypothesis testing was applied when appropriate. Pearson’s correlation was used to evaluate significance of correlation between total and allele-specific measurement of CEBPG in A549 cDNA and ChIP samples.

Results
Performance testing of allele-specific competitive PCR reagents
4 allele-specific primer sets were designed for each allele at the reporter polymorphic site rs2772, each with a 3’ mismatch over the polymorphic site and 3/4 that contained 1 of 3 possible mismatches at the 3’ penultimate base (Fig. 1A, B and supplementary materials online). All 4 primer sets tested for each allele, only the primer sets combining CEBPG rs2772 F1 primer with either CEBPG rs2772 R-A3 primer (A allele primer) or CEBPG rs2772 R-C3 primer (C allele primer) met allele-specific performance criteria of less than 5% non-targeted allele amplification, as demonstrated in electropherograms.
depicted in Figure 1D. As described before, to assess linearity of signal response, we titrated heterozygous native template relative to allele-specific internal standards over a 16-fold range in the presence of a constant amount of allele-specific internal standard mixture.\textsuperscript{14} The acceptable threshold performance criterion for each allele was a signal-to-analyte response associated with an $R^2 \geq 0.95$ in triplicate (Fig. 1C). Importantly, A and C alleles exhibited nearly identical slopes of signal-to-analyte response ($R^2 = 0.9877$ and $R^2 = 0.9849$, respectively; Fig. 1C). Performance observations for each primer set tested are annotated in supplementary materials online. Analytical variation was low both for replicate log-transformed measurements of cDNA samples (average analytical $CV = 12.7\%$) as well as gDNA samples (average analytical $CV = 14.9\%$). Importantly, each gDNA sample assessed did not deviate significantly from a 1:1 relationship between A and C alleles at rs2772, indicating absence of genomic copy number variation among all samples assessed.

Cell-cycle synchronization

A549 cells were successfully synchronized using double thymidine block (Fig. 2A and B). The majority of cells (67.4\%) in the no-block condition were observed to be in the G1 phase of the cell-cycle. Following synchronization, a majority of cells (60.1\%, 63.8\%, 77.1\% and 60.0\%) were in S phase during the 0, 2, 4 and 6 hour time points respectively, while most cells (82.5\% and 89.5\%) were in G1 during the 10 and 12 hour time points respectively. Notably, 80.0\% of cells were evenly split between G1 and G2/M during 8 hour time point, which is consistent with an observed doubling of the number of cells harvested between 8 and 10 hour time points [data not shown].

Total expression throughout cell-cycle

E2F1 and CEBPG transcript are at their maximum expression during G1/S transition (No Block and 0 hour time points) and decrease shortly thereafter (Fig. 2B and C). E2F1 total transcript displayed significantly higher expression during no block and 0 hour time points compared to 2, 6, 8 and 10 hours ($P < 0.05$), (Fig. 2C). CEBPG total transcript expression during the block and 0 hour time points was significantly higher than all other time points assessed ($P < 0.01$), (Fig. 2C).

RNAPII activity throughout cell-cycle

Cell-cycle dependent changes in expression of E2F1 transcript are, in part, regulated at the level of transcription.\textsuperscript{20} For this reason we chose to use RNA polymerase II phosphorylated at serine 2 (RNAPII) bound to a transcribed portion of E2F1 locus as a biological positive control for changes in transcriptional activity throughout the cell-cycle. In these studies we compared positive control ChIP measurements of level of RNAPII bound to E2F1 gene (E2F1-RNAPII) and RNAPII bound to CEBPG gene (CEBP-G-RNAPII). RNAPII bound to E2F1 genomic locus for No Block, and 10 and 12 hour time points were significantly higher than all other time points ($P < 0.05$), (Fig. 2D). In contrast, there was no significant deviation in total number of CEBPG-RNAPII molecules between all time points ($P > 0.05$), (Fig. 2D). Importantly, E2F1-RNAPII molecules trended throughout the cell-cycle (Fig. 2D) similarly to total E2F1 transcript expression (Fig. 2C), as well as percentage of cells in G1 phase of the cell-cycle (Fig. 2B). CEBPG-RNAPII molecules did not display a similar trend to CEBPG total expression that we observed for E2F1 (Fig. 2C and D).

CEBP-G allele-specific expression and RNAPII allele-specific activity

In cell-cycle synchronized A549 cells, CEBPG exhibited allele-specific expression ratios at polymorphic site rs2772 (A:C) ranging from 1.24 to 1.75 (normalized to A549 gDNA; average of 0.94) (Fig. 2E). Meanwhile, control measurement of actively transcribing RNAPII bound to CEBPG locus (CEBP-G-RNAPII) was not significantly different than the null hypothesis of measuring a ratio of 0.94 ($P = 0.09$). On average, the measured ASE A:C ratio was 1.49 (Fig. 2E). Of note, for time points 0 through 12 hours post DTB (removing no-block control from analysis) the slope of CEBPG rs2772 A allele total expression relative to overall total CEBPG expression ($y = 0.742x; R^2 = 0.998$) was nearly 2.9-fold higher ($P < 0.001$) higher than that for rs2772 C allele ($y = 0.258x; R^2 = 0.993$) (Fig. 2F).
Allele-specific expression measurement of CEBPγ transcript in NBEC samples

CEBPγ allele-specific transcript expression was measured in NBEC cDNA samples from 15 individuals heterozygous at transcribed reporter polymorphic site rs2772 and with varying allelotype at other putative regulatory polymorphic sites rs736682, rs17530479, rs17530508, rs1469084, rs16968029, rs3745968 and rs36101103 (Figs. 1 and 3, and Table 2). To control for potential genomic copy number variation, CEBPγ allelic ratio was measured in gDNA samples from the same 15 individuals. Observed allele-specific expression ratios according to genotype are displayed in Figure 3. There was significantly higher ($P < 0.001$) inter-sample variation in allelic ratio measured at polymorphic site rs2772 for the group of fifteen NBEC cDNA (biological CV = 44.2%) compared to corresponding gDNA controls (biological CV = 9.8%). On an individual basis, the A:C ratio (allelic imbalance) was significantly higher ($P < 0.05$; after Bonferroni correction) relative to gDNA control ratios for
CEBPG exhibits allele-specific expression in the airway

3 subjects (247, 289 and 521) (Fig. 3 and Table 2). Importantly, only polymorphic site rs2772 was heterozygous in each of these 3 individuals, indicating it is the most likely candidate influencing CEBPG ASE.

**Discussion**

Traditional causes of allele-specific expression (ASE), such as genomic imprinting or X-chromosome inactivation are associated with complete silencing of expression from an allele or an individual parental chromosome. In contrast, it is now known that a large percentage of non-imprinted autosomal genes exhibit a more subtle type of ASE, such as that observed with CEBPG in this study (Figs. 2 and 3). In this latter form of ASE, inter-allelic difference in expression typically varies approximately 1.2- to 1.6-fold away from an expected 1.0 ratio of expression between parental chromosomes. Importantly, ASE from these non-imprinted autosomal genes exhibit Mendelian patterns of inheritance. These observations suggest that subtle inter-allelic variation in expression is at least in part explained by variation in proximal (ie, cis-acting) sequences, differentially affecting the transcript expression abundance of alleles derived from each parental chromosome, and is a separate entity from classical imprinting phenomenon.
CEBPG total expression exhibited a cell-cycle specific profile similar to that of E2F1 (Fig. 2C). Yet, active RNAPII varied minimally at the CEBPG genomic locus compared to E2F1 measured RNAPII activity (Fig. 2D). In addition, although significant CEBPG ASE was observed, RNAPII allele-specific transcriptional activity was not (Fig. 2E). This suggests that regulation of both total and allele-specific CEBPG transcript expression is partly regulated at the post-transcriptional level. Further, during the course of the cell-cycle there was a 2.9-fold difference between rs27772 A and C alleles in responsiveness to factor(s) that regulate CEBPG total transcript levels (Fig. 2F). Accumulating evidence indicates that in order for cis-acting genetic variants to differentially regulate ASE, they must respond differently to trans-acting factors.\textsuperscript{15,26,27} If the trans-effect is constitutive in the tissue assessed, ASE should tightly associate with specific cis-genotypes in the population.\textsuperscript{14,28,29} Conversely, if there is inter-individual variation in trans-acting factor function, for example throughout the cell-cycle or in response to other environmental effects, ASE that is mechanistically important may be associated with cis-acting genetic variants in only some individuals.\textsuperscript{27} In the cell cycle model presented here, cis-regulatory elements were constant, and hence the cause of variation in total and allele-specific CEBPG expression must have been due to variation in the total level of trans-factor activity operating downstream of RNAPIII transcription of CEBPG (ie, post-transcriptional; Fig. 2F).

In order for cis-acting genetic variation to influence the post-transcriptional regulation of CEBPG, the polymorphic cis-element must be transcribed and present in the mRNA. Thus, the most plausible polymorphic cis-element that would explain the phenomenon observed here is rs27772 (3’UTR), and less likely rs17530479 (promoter region). As has been described for other genes,\textsuperscript{30} genetic variation at a miRNA regulatory motif within the transcribed portion of CEBPG could alter post-transcriptional levels of CEBPG. Inputting CEBPG 3’UTR polymorphic site rs27772 into MirSNP database reveals that the C allele, but not the A allele, is a target site for miRNA hsa-miR-1248.\textsuperscript{31} This finding is consistent with our observations that rs27772 C allele is on average expressed 2-fold lower than rs27772 A allele. Based on the literature, miRNA hsa-miR-1248 is upregulated during de-differentiation as well as epithelial inflammation,\textsuperscript{32,33} which is consistent with known effects of perturbing CEBPG expression.\textsuperscript{3–6}

Normal human bronchial epithelial cells in vivo are typically quiescent.\textsuperscript{34,35} This information, combined with the fact that CEBPG total and allele-specific expression is regulated post-transcriptionally by a trans-effect(s) that is variable in activity (Fig. 2C and D), may explain why only 20% of primary NBEC samples assessed in this study, heterozygous for rs27772, exhibited allele-specific CEBPG expression (Fig. 3). Specifically, we observed that CEBPG rs27772 A allele was expressed 2.10-fold higher than C allele in 3 of 15 (20%) NBEC samples heterozygous for polymorphic site rs27772. This finding is interesting in light of a previous report by Lo et al, who observed that the CEBPG polymorphic site rs27772 A allele was expressed 2.42-fold higher than the C allele in 20% of fetal kidney tissues.\textsuperscript{24}

Numerous approaches for allele-specific transcript measurement have been described,\textsuperscript{13} and many of these techniques rely upon the intrinsic quality control inherent in measuring relative allelic levels within a single reaction vessel. Despite this built-in quality control step, numerous additional known and unknown sources of analytical variation remain uncontrolled by this method alone and can potentially result in inaccurate and low precision of ASE measurement.\textsuperscript{17,36,38} In this study we implemented multiple additional quality control measures to address some of the potential sources of analytical error encountered in ASE association studies. Key to this effort was adaption of competitive PCR to allele-specific quantification. Properly designed competitive PCR offers highly reproducible measurement of DNA template copy numbers, wide linear dynamic range, superb target analyte specificity, and relatively low cost.\textsuperscript{16,17} Allele-specific competitive PCR combines competitive PCR with previously described allele-specific PCR priming\textsuperscript{22} to precisely and accurately quantify alleles (Fig. 1).

In summary, we report that (a) rs27772 A allele expression varied approximately 2- to 3-fold more than rs27772 C allele during cell-cycling, (b) there was no significant correlation between RNAPII activity and observed CEBPG ASE in the cell-cycle synchronized A549 cell-line model, and (c) polymorphic site rs27772 in Exon 2 of CEBPG exhibited...
allele-specific expression in adult NBEC samples from some subjects, but not others. Thus, there is support for the hypothesis that cis-acting variants participate in regulation of CEBPG transcript levels and this partly explains inter-individual variation in CEBPG expression in NBEC. Importantly, the data suggest that a mechanism other than RNAPII mediated transcription regulation is responsible for this observed variation in ASE. Because CEBPG is an important regulator of airway epithelial proliferation and development, cis-acting genetic variation that alters the expression of CEBPG at the cusp of G1 and S phase has a high likelihood of involvement in the manifestation of a variety of lung pathologies, possibly through effects on CEBPA regulation of E2F1 activity, or as a downstream modulator of JNK/JunD mediated proliferation. Future work towards mechanistic understanding, including the responsible trans-acting factor, for association of genetic variant rs2772 with post-transcriptional regulation of CEBPG ASE in NBEC may result in improvement in screening and treatment for a variety of lung diseases. Prior data from this laboratory support the hypothesis that CEBPG coordinates regulation of key DNA repair and antioxidant genes in NBEC, and in other human epithelial cell models CEBPG plays a key role in regulation of cell proliferation. Based on these observations, additional studies are justified to further understand the exact mechanistic relationship between rs2772 genetic variation and inter-individual variation in CEBPG expression contributing to variation in the vitally important coordination of DNA repair with cell cycling.

Acknowledgements
We would like to thank the following individuals for their contribution: Thomas Sawyer and Karen Domenico for their expertise in flow-cytometric analysis.

Author Contributions
TMB conceived the research design, designed the reagents, supervised experiments and data analysis, and contributed to the writing of this manuscript. RDB conducted the experiments and data analysis, and contributed to the writing of this manuscript. ELC supervised experiments and contributed to the writing of this manuscript. YY and DAH assisted in collection of blood and bronchial epithelial cell brushings. IS supervised chromatin immunoprecipitation studies and associated data analysis. KW supervised cell-cycle studies and associated data analysis. JCW supervised the entirety of the research design, conduct of the experiments, data analysis, and writing of this manuscript.

Funding
National Institutes of Health (CA95806, CA103594, CA132806 to JCW) and George Isaac Research Fund.

Competing Interests
JCW has significant equity interest in Accugenomics, which produces and markets StaRT-PCR™ reagents used in this study. Other authors disclose no competing interests.

Disclosures and Ethics
As a requirement of publication the authors have provided signed confirmation of their compliance with ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research participants (if applicable), and that permission has been obtained for reproduction of any copyrighted material. This article was subject to blind, independent, expert peer review. The reviewers reported no competing interests.

References
1. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 2002;365:561–75.
2. Cooper C, Henderson A, Artandi S, Avitahl N, Calame K. Ig/EBP (C/EBP gamma) is a transdominant negative inhibitor of C/EBP family transcriptional activators. Nucleic Acids Res. 1995;23:4371–7.
3. Crawford EL, Blomquist T, Mullins DN, et al. CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions. Carcinogenesis. 2007;28:2552–9.
4. Mullins DN, Crawford EL, Khuder SA, Hernandez DA, Yoon Y, Willey JC. CEBPG transcription factor correlates with antioxidant and DNA repair genes in normal bronchial epithelial cells but not in individuals with bronchogenic carcinoma. BMC Cancer. 2005;5:141.
5. Blomquist T, Crawford EL, Mullins D, et al. Pattern of antioxidant and DNA repair gene expression in normal airway epithelium associated with lung cancer diagnosis. Cancer Res. 2009;69:8629–35.
6. Kaisho T, Tsutsui H, Tanaka T, et al. Impairment of natural killer cytotoxic activity and interferon gamma production in CCAAT/enhancer binding protein gamma-deficient mice. J Exp Med. 1999;190:1573–82.
7. Fodoby P, Barlow C, Kylefjord H, Ahlbrand-Richter L, Xanthopoulos KG. Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha. J Biol Chem. 1996;271:24753–60.
8. Wang ND, Finegold MJ, Bradley A, et al. Impaired energy homeostasis in C/EβP alpha knockout mice. *Science*. 1995;269:1108–12.

9. Loomis KD, Zhu S, Yoon K, Johnson PF, Smart RC. Genetic ablation of CCAAT/enhancer binding protein alpha in epidermis reveals its role in suppression of epithelial tumorigenesis. *Cancer Res*. 2007;67:6768–76.

10. Alvarado DM, Hawkins RD, Bashardes S, et al. An RNA interference-based screen of transcription factor genes identifies pathways necessary for sensory regeneration in the avian inner ear. *J Neurosci*. 2011;31:4535–43.

11. Gu Y, Harley IT, Henderson LB, et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. *Nature*. 2009;458:1039–42.

12. Pastinen T. Genome-wide allele-specific analysis: insights into regulatory variation. *Nat Rev Genet*. 2010;11:553–8.

13. Knight JC. Allele-specific gene expression uncovered. *Trends Genet*. 2004;20:113–6.

14. Blomquist TM, Crawford EL, Willey JC. Cis-acting genetic variation at an E2F1/YY1 response site and putative p53 site is associated with altered allele-specific expression of ERCC5 (XPG) transcript in normal human bronchial epithelium. *Carcinogenesis*. 2010;7:1242–50.

15. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP. In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. *Nat Genet*. 2003;33:469–75.

16. Willey JC, Crawford EL, Jackson CM, et al. Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. *Am J Respir Cell Mol Biol*. 1998;19:6–17.

17. Canales RD, Luo Y, Willey JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. *Nat Biotechnol*. 2006;24:1115–22.

18. Bostock CJ, Prescott DM, Kirkpatrick JB. An evaluation of the double thymidine block for synchronizing mammalian cells at the G1-S border. *Exp Cell Res*. 1971;68:163–8.

19. Schroering AG, Williams KJ. Rapid induction of chromatin-associated DNA mismatch repair proteins after MNN treatment. *DNA Repair (Amst)*. 2008;7:951–69.

20. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. *Genes Dev*. 1994;8:1514–25.

21. McDonald JH. *Handbook of Biological Statistics*. Baltimore: Sparky House Publishing; 2008:145–7.

22. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). *Nucl Acids Res*. 1989;17:2503–16.

23. Cowles CR, Hirschhorn JN, Altshuler D, Lander ES. Detection of regulatory variation in mouse genes. *Science*. 2002;297:1143.

24. de la Chapelle A. Genetic predisposition to human disease: allele-specific expression and low-penetrance regulatory loci. *Oncogene*. 2009;28:3345–8.

25. Grundberg E, Adoue V, Kwan T, et al. Global analysis of the impact of environmental perturbation on cis-regulation of gene expression. *PLoS Genet*. 2011;7:e1001279.

26. Campino S, Forton J, Raj S, et al. Validating discovered Cis-acting regulatory genetic variants: application of an allele specific expression approach to HapMap populations. *PLoS One*. 2008;3:e4105.

27. Pastinen T, Ge B, Hudson TJ. Influence of human genome polymorphism on gene expression. *Hum Mol Genet*. 2006;15(Spec No 1):R9–16.

28. Loomis KD, Zhu S, Yoon K, Johnson PF, Smart RC. Allele-specific gene expression uncovered. *Trends Genet*. 2004;20:113–6.

29. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP. In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. *Nat Genet*. 2003;33:469–75.

30. Willey JC, Crawford EL, Jackson CM, et al. Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. *Am J Respir Cell Mol Biol*. 1998;19:6–17.

31. Canales RD, Luo Y, Willey JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. *Nat Biotechnol*. 2006;24:1115–22.

32. Lin L, Shen Q, Zhang C, Chen L, Yu C. Assessment of the profiling microRNA expression of differentiated and dedifferentiated human adult articular chondrocytes. *J Orthop Res*. 2011;29:1578–84.

33. Song JJ, Kwon SK, Cho CG, Park SW, Chae SW. Microarray analysis of microRNA expression in LPS induced inflammation of human middle ear epithelial cells (HMEECs). *Int J Pediatr Otorhinolaryngol*. 2011;75:648–51.

34. Uhal BD. Cell cycle kinetics in the alveolar epithelium. *Am J Physiol*. 1997;272:L1031–45.

35. Herzog EL, Brody AR, Colby TV, Mason R, Williams MC. Knowns and unknowns of the alveolus. *Proc Am Thorac Soc*. 2008;5:778–82.

36. Willey JC, Crawford EL, Knight CA, et al. Use of Standardized Mixtures of Internal Standards in Quantitative RT-PCR to Ensure Quality Control and Develop a Standardized Gene Expression Database. In: Bustin SA, editor. *A-Z of Quantitative PCR*. La Jolla: International University Line; 2004: 545–76.

37. Cirulli ET, Goldstein DB. In vitro assays fail to predict in vivo effects of regulatory polymorphisms. *Hum Mol Genet*. 2007;16:1931–9.

38. Liljedahl U, Fredriksson M, Dahlgren A, Syvänen AC. Detecting imbalanced expression of SNP alleles by minisequencing on microarrays. *BMC Biotechnol*. 2004;4:24.

39. Willey JC, Crawford EL, Knight CR, et al. Standardized RT-PCR and the standardized expression measurement center. *Methods Mol Biol*. 2004;258:13–41.
Supplementary Methods Text

Controls in allele-specific competitive PCR

By measuring the transcript expression of a gene relative to a known number of internal standard molecules within a standardized mixture of internal standards, all known sources of variation during PCR can be controlled. This generates data that are directly comparable across multiple experiments and institutions [39]. This method prevents false negatives because if the PCR fails, the internal standard product is not observed and there are no data to report. Likewise, false positives are eliminated by using internal standard only (no native allele) (Fig. 1D i) and water only controls. The experimental design used to measure the abundance of alleles present in a mixture of native template DNA relative to a known number of Allele-Specific Internal Standard DNA template molecules is show to the left. Actual electropherograms of PCR reaction products from experiment, are depicted in Figure 1D.

Chromatin immunoprecipitation cell preparation

Following cell-cycle synchronization, an aliquot of cells from each time point was processed for ChIP analysis. These cells were incubated in 1% formaldehyde solution, gently rocking, at room temperature for 15 minutes, followed by incubation in 2.5 M glycine solution for 5 minutes to quench unreacted formaldehyde. Cross-linked cells were then pelleted and resuspended in 1x PBS. Next, cells were pelleted and resuspended in SDS lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS, 5 µM AEBSF, 1.5 µM Aprotinin, 10 nM E-64, 10 nM Leupeptin, 0.1 mM Sodium Fluoride, 2 nM Sodium Orthovanidate, 20 nM Sodium Pyrophosphate and 20 nM B-Glycerophosphate). Samples in SDS lysis buffer were sonicated on ice using a Cole Palmer Sonicator (Model CPX130) at 80% amplitude for 3 minutes at 30 second intervals with at least one minute to cool between intervals. To achieve a median fragmentation length of 300 bp, sonicated cell lysates were then centrifuged at 4 °C for 10 minutes at 12,000 g to pellet unsonicated cellular debris. The supernatant was recovered, measured for chromatin DNA concentration (NanoDrop 2000 Spectrophotometer, Thermo Scientific, using dsDNA measurement tab) and distributed into 50 µg chromatin aliquots in 1 mL of IP buffer (15 mM Tris-HCl, 165 mM NaCl, 1 mM EDTA, 1.0% Triton X-100, 5 µM AEBSF, 1.5 µM Aprotinin, 10 nM E-64, 10 nM Leupeptin, 0.1 mM Sodium Fluoride, 2 nM Sodium Orthovanidate, 20 nM Sodium Pyrophosphate and 20 nM B-Glycerophosphate). Purified input sonicate DNA was run on 2% agarose gel to assess fragmentation using NIH Image J software.

Chromatin immunoprecipitation

100 µL aliquots of Protein G Dynabeads for each immunoprecipitation (Dynabeads Protein G, Invitrogen Dynal AS, Oslo, Norway) were washed three times in Block Solution (1x PBS, 0.5% bovine serum albumin), followed by addition of 10 µg of antibody of interest (normal rabbit polyclonal IgG sc-2027, Santa Cruz Biotechnology; or rabbit polyclonal to RNA polymerase II CTD repeat YSPTSPS phospho S2, Abcam Inc.), and incubated on a rotator overnight at 4 °C. Next, Dynabeads were washed three times in Block Solution to remove unbound antibody and resuspended in 100 µL of Block Solution. At this time, 50 µg aliquots of chromatin cell lysate in 1 mL of IP buffer was added and mixed together followed by incubation on a rotator overnight at 4 °C. Beads were collected using magnetic particle concentrator to allow removal of unbound chromatin, followed by individual consecutive washes with 150 mM NaCl (20 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 1.0% Triton X-100, 0.1% SDS), 250 mM LiCl (10 mM Tris-HCl, 250 mM LiCl, 1 mM EDTA, 1.0% NP-40, 1.0%
Na-Deoxycholate) and TE + 50 mM NaCl (10 mM Tris-HCl, 1 mM EDTA, 50 mM NaCl) respectively. Next, solution was spun at 960×g to remove any residual TE + 50 mM NaCl buffer. Elution buffer (50 mM Tris-HCl, 10 mM EDTA, 1.0% SDS) was added and samples were vortexed at 5 minute intervals while incubating at 65 °C for 30 minutes. Next, elution buffer with beads was spun at 16000×g and supernatant containing eluted and enriched DNA-protein complexes was removed from pelleted beads and incubated at 65 °C for 6 hours to reverse formaldehyde cross-linking. Next, samples were Proteinase K treated overnight at 37 °C, followed by heat-stop reaction and purification using QIAEX II DNA purification kit (Qiagen, Inc., USA) to recover enriched DNA.

Table S1. PCR and competitive PCR primer sequences.

| Primer # | Primer name       | Sequence (5’ to 3’) | Notes                                                                 |
|----------|-------------------|---------------------|----------------------------------------------------------------------|
| 1        | CeBPG rs2772 R   | AGA TCT AAC AGC TGC AGA ATG G | Reverse primer for pre-amplification of both A and C allele at rs2772. |
|          | common           |                     |                                                                      |
| 2        | CeBPG rs2772 R-A1| AGA TCT AAC AGC TGC AGA ATG GA | Matches A allele at rs2772. Did not meet allele-specificity criteria. |
| 3        | CeBPG rs2772 R-A2| AGA TCT AAC AGC TGC AGA ATG AA | Matches A allele at rs2772 with 3’ pen-ultimate mismatch. Pen-ultimate mismatch decreased overall PCR efficiency, however it did achieve allele-specificity criteria. |
| 4        | CeBPG rs2772 R-A3| AGA TCT AAC AGC TGC AGA ATG TA | Matches A allele at rs2772 with 3’ pen-ultimate mismatch. Good PCR efficiency and met allele-specificity criteria. Used with CeBPG rs2772 F1 primer for ASE of CeBPG. |
| 5        | CeBPG rs2772 R-A4| AGA TCT AAC AGC TGC AGA ATG CA | Matches A allele at rs2772 with 3’ pen-ultimate mismatch. Pen-ultimate mismatch decreased overall PCR efficiency, however it did achieve allele-specificity criteria. |
| 6        | CeBPG rs2772 R-C1| AGA TCT AAC AGC TGC AGA ATG GC | Matches C allele at rs2772. Good PCR efficiency and met allele-specificity criteria. |
| 7        | CeBPG rs2772 R-C2| AGA TCT AAC AGC TGC AGA ATG AC | Matches C allele at rs2772 with 3’ pen-ultimate mismatch. Good PCR efficiency and met allele-specificity criteria. |
| 8        | CeBPG rs2772 R-C3| AGA TCT AAC AGC TGC AGA ATG TC | Matches C allele at rs2772 with 3’ pen-ultimate mismatch. Good PCR efficiency and met allele-specificity criteria. Used with CeBPG rs2772 F1 primer for ASE of CeBPG in order to maintain consistency of 3’ pen-ultimate mismatch between both allele-specific primers. |
| 9        | CeBPG rs2772 R-C4| AGA TCT AAC AGC TGC AGA ATG CC | Matches C allele at rs2772 with 3’ pen-ultimate mismatch. Pen-ultimate mismatch decreased overall PCR efficiency, however it did achieve allele-specificity criteria. Artifact peaks present. |
| 10       | CeBPG rs2772 F1  | TTT CCC AGT CCC CAT TAG AGG | Forward primer used for general pre- and allele-specific amplification. |
| 11       | CeBPG rs2772 IS A allele | AGA TCT AAC AGC TGC AGA ATG GAA AAC AAA ACA ATT CTC CTA AGG C | Primer coupled with CeBPG rs2772 F1 to create A allele competitive template. |
| 12       | CeBPG rs2772 IS C allele | AGA TCT AAC AGC TGC AGA ATG GCT TCT CCT AAG GCA TCA GA | Primer coupled with CeBPG rs2772 F1 to create C allele competitive template. |